A Memorial Sloan-Kettering Cancer Center team has shown that CXC chemokine receptor 2 antagonists sensitized tumors to chemotherapy in mice with metastatic breast cancer. The team is working on additional preclinical studies with the intention of moving the antagonists into clinical trials for breast cancer.